Literature DB >> 3489874

Activating and 'anxiogenic' effects of corticotropin releasing factor are not inhibited by blockade of the pituitary-adrenal system with dexamethasone.

K T Britton, G Lee, R Dana, S C Risch, G F Koob.   

Abstract

Central administration of corticotropin releasing factor (CRF) in rats produces pituitary-adrenal activation and a variety of "anxiogenic-like" effects. The present study was designed to explore the contribution of the peripheral pituitary-adrenocortical axis in mediating these CRF responses. Intraventricularly administered CRF produced suppression of responding in the conflict test and a marked locomotor activation. Neither behavioral effect was altered by the prior administration of dexamethasone in a dose that blocked pituitary-adrenal activation to CRF. These results support the hypothesis that behavioral effects of CRF are mediated by its action at central sites and not via an action on the pituitary-adrenocortical system.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3489874     DOI: 10.1016/0024-3205(86)90189-x

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  19 in total

Review 1.  Evidence for the role of corticotropin-releasing factor in major depressive disorder.

Authors:  R Parrish Waters; Marion Rivalan; D A Bangasser; J M Deussing; M Ising; S K Wood; F Holsboer; Cliff H Summers
Journal:  Neurosci Biobehav Rev       Date:  2015-08-10       Impact factor: 8.989

2.  The psychomodulatory action of subpyrogenic doses of interleukin-1beta in conditions of chronic administration to rats.

Authors:  E S Sokolova; V I Lyudyno; A S Simbirtsev; V M Klimenko
Journal:  Neurosci Behav Physiol       Date:  2007-06

3.  CRF mediates the anxiogenic and anti-rewarding, but not the anorectic effects of PACAP.

Authors:  Riccardo Dore; Attilio Iemolo; Karen L Smith; Xiaofan Wang; Pietro Cottone; Valentina Sabino
Journal:  Neuropsychopharmacology       Date:  2013-05-09       Impact factor: 7.853

4.  CP-154,526: a potent and selective nonpeptide antagonist of corticotropin releasing factor receptors.

Authors:  D W Schulz; R S Mansbach; J Sprouse; J P Braselton; J Collins; M Corman; A Dunaiskis; S Faraci; A W Schmidt; T Seeger; P Seymour; F D Tingley; E N Winston; Y L Chen; J Heym
Journal:  Proc Natl Acad Sci U S A       Date:  1996-09-17       Impact factor: 11.205

5.  Proceedings of the British Pharmacological Society Meeting. Sheffield, 18-20th April 1990.

Authors: 
Journal:  Br J Pharmacol       Date:  1990-06       Impact factor: 8.739

6.  Gender-specific association of galanin polymorphisms with HPA-axis dysregulation, symptom severity, and antidepressant treatment response.

Authors:  Paul G Unschuld; Marcus Ising; Darina Roeske; Angelika Erhardt; Michael Specht; Stefan Kloiber; Manfred Uhr; Bertram Müller-Myhsok; Florian Holsboer; Elisabeth B Binder
Journal:  Neuropsychopharmacology       Date:  2010-03-17       Impact factor: 7.853

Review 7.  Molecular pathways of anxiety revealed by knockout mice.

Authors:  S J Wood; M Toth
Journal:  Mol Neurobiol       Date:  2001 Apr-Jun       Impact factor: 5.590

8.  A sexually dimorphic distribution of corticotropin-releasing factor receptor 1 in the paraventricular hypothalamus.

Authors:  Zachary J Rosinger; Jason S Jacobskind; Rose M De Guzman; Nicholas J Justice; Damian G Zuloaga
Journal:  Neuroscience       Date:  2019-05-02       Impact factor: 3.590

Review 9.  Physiological and neurochemical aspects of corticotropin-releasing factor actions in the brain: the role of the locus coeruleus.

Authors:  H Lehnert; C Schulz; K Dieterich
Journal:  Neurochem Res       Date:  1998-08       Impact factor: 3.996

10.  MPZP: a novel small molecule corticotropin-releasing factor type 1 receptor (CRF1) antagonist.

Authors:  Heather N Richardson; Yu Zhao; Eva M Fekete; Cindy K Funk; Peter Wirsching; Kim D Janda; Eric P Zorrilla; George F Koob
Journal:  Pharmacol Biochem Behav       Date:  2007-10-23       Impact factor: 3.533

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.